Search Medical Condition
Please enter condition
Please choose location

Darien, Connecticut Clinical Trials

A listing of Darien, Connecticut clinical trials actively recruiting patient volunteers.

RESULTS

Found (86) clinical trials

VIRTUS: An Evaluation of the Veniti Vici Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow Obstruction

The objective of this prospective study is to assess the safety and efficacy of the Veniti Vici™ Venous Stent System in achieving patency of the target venous lesion in patients with clinically significant chronic non-malignant obstruction of the iliofemoral venous outflow tract.

Phase N/A

0.75 miles

Learn More »

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic Endovascular System

The study is designed to evaluate the safety and efficacy of ultrasound accelerated thrombolysis using the EkoSonic® Endovascular System with standard infusion of a thrombolytic drug for PTS and chronic DVT. Clinical effectiveness will be evaluated using a standard measure of severity of post-thrombotic syndrome over a year.

Phase N/A

0.75 miles

Learn More »

A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease

This study will evaluate Advanced Laboratory Services Borrelia diagnostic test by culturing Borrelia spirochetes from human serum in subjects with early or late Lyme disease. This is an 8 month study. Subjects entering the study will have two blood samples collected one month apart if they have early Lyme disease ...

Phase N/A

0.75 miles

Learn More »

Revolution Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization

This study intends to enroll up to 121 subjects at up to 12 investigational sites in the United States. This is a single-arm study of the Revolution™ Peripheral Atherectomy System in subjects with peripheral arterial disease (PAD). The primary safety endpoint is freedom from 30-day Major Adverse Events (MAE), defined ...

Phase N/A

0.75 miles

Learn More »

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect)-controlled, event-driven, multicenter study in patients who are hospitalized ...

Phase

3.08 miles

Learn More »

A Study of LY2951742 in Participants With Episodic Cluster Headache

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as LY2951742 in participants with episodic cluster headaches.

Phase

3.08 miles

Learn More »

A Study of Modified Stem Cells in Traumatic Brain Injury (TBI)

SB623 cells are adult bone-marrow-derived cells that are transiently transfected with a plasmid construct encoding the intracellular domain of human Notch-1. These cells produce trophic factors that protect neurons in models of ischemic insult. In a rat contusion model of TBI, implantation of SB623 around the area of the injury ...

Phase

3.08 miles

Learn More »

A Study of LY2951742 in Participants With Chronic Cluster Headache

The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with chronic cluster headache.

Phase

3.08 miles

Learn More »

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

This study will evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

Phase

3.08 miles

Learn More »

Longitudinal Evaluation of [18F]MNI-798 as a PET Radioligand for Imaging Tau in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers

The purpose of this protocol is to evaluate the longitudinal change in tau burden using [18F]MNI-798, tau targeted radiopharmaceutical compared to baseline in prodromal, mild, and moderate AD subjects and in similarly-aged HV subjects.

Phase

3.08 miles

Learn More »